Avance Clinical Highlights Oncology Expertise at ASCO 2026
CHICAGO, Ill., June 20, 2026 Avance Clinical, a leading global Contract Research Organization (CRO) specializing in accelerating clinical development...
AI drug discovery artificial intelligence Autoimmune Disease biologics Biomarkers biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology immunology Immunotherapy Medical Device Medical Devices MedTech Monoclonal Antibody Neurodegenerative Disease Neurology Oncology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
CHICAGO, Ill., June 20, 2026 Avance Clinical, a leading global Contract Research Organization (CRO) specializing in accelerating clinical development...
LEXINGTON, Mass., May 21, 2026 Accent Therapeutics has announced the presentation of a Trial in Progress poster for its...
INGELHEIM, Germany & RIDGEFIELD, Conn., May 21, 2026 Boehringer Ingelheim has unveiled significant new oncology data at the 2026...
TARPON SPRINGS, Fla., March 6, 2026 Allarity Therapeutics, Inc., a clinical-stage biopharmaceutical company, has announced the successful closing of...
RARITAN, N.J., Feb. 19, 2026 — Johnson & Johnson announced new Phase 1b/2 clinical data demonstrating that subcutaneous RYBREVANT...
BOSTON, Mass., Feb. 20, 2026 — New clinical findings presented at a major oncology symposium demonstrate that ficerafusp alfa...
LEXINGTON, Mass., Feb. 19, 2026 — Agenus Inc. announced new translational and clinical biomarker findings demonstrating survival stratification in...
DUBLIN, IRELAND | January 27, 2026 — ICON plc, a global clinical research organization, announced a significant expansion of...
WESTLAKE VILLAGE, Calif. | January 5, 2026 — Genelux Corporation, a late clinical-stage immuno-oncology company, has reported encouraging interim...
BARCELONA, Spain, Oct. 8, 2025 — During the 2025 Annual Congress of the European Association of Nuclear Medicine (EANM...
